Ilube

ILUBE 5% w/v Eye Drops, Solution

acetylcysteine 5.0% w/v

Excipient(s) with known effect

Benzalkonium chloride 0.01% w/v.

For the full list of excipients, see section 6.1.

Eye drops, solution

A clear and colourless eye drops solution.

ILUBE Eye Drops are artificial tears with mucolytic and lubricant properties, suitable for the relief of dry eye syndromes associated with deficient tear secretion, impaired or abnormal mucus production.

Posology

The usual dose is 1 or 2 drops instilled into the affected eye(s) 3 or 4 times daily.

Paediatric population

No data are available.

Method of administration

ILUBE Eye Drops are administered by topical instillation into the conjunctival sac.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

ILUBE Eye Drops contain benzalkonium chloride which may cause eye irritation or discolour soft contact lenses. Avoid contact with soft contact lenses. Patients should be instructed to remove contact lenses prior to application and wait at least 15 minutes before reinsertion. Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface. Should be used with caution in dry eye patients and in patients where the cornea may be compromised. Patients should be monitored in case of prolonged use.

No interaction studies have been performed.

Medical advice must be sought before taking ILUBE Eye Drops with any medication, including medicines obtained without a prescription.

This product should not be taken if the patient is pregnant, might get pregnant, or is breast-feeding without seeking medical advice.

Patients must be advised that their vision may be blurred after using Ilube Eye Drops and must not drive or use any machines, unless their vision is clear.

Patient may experience itching, redness and/ or irritation in their eye(s).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

None known

Pharmacotherapeutic Group: Ophthalmologicals, other ophthalmologicals, ATC Code: S01X A08.

Acetylcysteine, a derivative of the naturally occurring amino acid L-cysteine, with marked mucolytic properties.

Acetylcysteine has been shown to dramatically reduce the viscosity and tenacity of sputum. The liquifying action is due to the presence of a free sulphydryl group which opens up disulphide bonds present in mucus. This pharmacological action of acetylcysteine is of benefit to patients suffering from ocular mucus abnormality.

This combined with the emollient properties of hypromellose, ensures lubrication and soothing relief for dry eye syndrome.

No specific work has been carried out on the pharmacokinetic properties of acetylcysteine when used as a topical preparation for the eye. Acetylcysteine reduces the viscosity and tenacity of mucus in the eye. This, combined with the emollient properties of hypromellose, ensures lubrication and soothing relief for dry eye syndromes.

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

Disodium edetate

Hypromellose

Benzalkonium chloride

Sodium hydroxide

Purified water

Not applicable.

2 years (unopened), 28 days (after first opening).

Do not store above 25°C.

Keep the bottle in the outer carton in order to protect from light. Keep the bottle tightly closed.

For storage conditions after first opening of the medicinal product, see section 6.3.

A lipped Type I amber glass bottle with a push-in closure (chlorobutyl bung) containing 10 ml of solution. The bung is held in place by a polypropylene and aluminium overseal. The bung and overseal form a single integral closure (“flipcap”). Immediately before use, the overseal and bung are removed and replaced with a polyvinyl chloride integral cap and dropper assembly, which fits over the lip of the bottle. The integral cap and dropper assembly has an aperture at the end for the delivery of the product, which is closed with a small high density polyethylene screw cap.

Discard 28 days after first opening the pack.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Rayner Pharmaceuticals Ltd,

10 Dominion Way,

Worthing,

West Sussex

BN14 8AQ,

United Kingdom

PLGB 47069/0008

Date of first authorisation: 17 December 1992

Date of last renewal: 25 June 2007

December 2022